Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in dyspnoea score · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in exercise tolerance · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in hospital utilisation ‐ not measured · chronic obstructive pulmonary disease (COPD) with depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Functional ability · people with systemic sclerosis
Autologous myeloablative selective HSCT may leads to higher functional ability – HAQ‐DIb Scale 0–3 with 0 representing no/mild… compared with cyclophosphamide (low certainty).
1 finding from 1 review
Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
Autologous myeloablative selective HSCT probably leads to higher skin thickness – mRSS Scale 0–51 in which a higher number is worse… compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
FVC · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in interstitial lung disease – FVC (% predicted) A lower percentage… compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Overall mortality · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in event‐free survival compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Frequency of attacks Per week (over 2 weeks) · primary Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Duration of attacks per day (minutes) · primary Raynaud's phenomenon
1 finding from 1 review
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon
It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found